checkAd

     129  0 Kommentare Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals

    Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversityNORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers Squibb Company Bristol Myers Squibb (NYSE: BMY) today published its 2023 …

    Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity

    NORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers Squibb Company

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    35,80€
    Basispreis
    0,43
    Ask
    × 8,77
    Hebel
    Short
    45,22€
    Basispreis
    0,46
    Ask
    × 8,20
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

    "For more than 130 years, BMS has enabled positive change for our patients around the world. As we navigate an increasingly complex global landscape, our ESG strategy has never been more important to driving long-term business value and fulfilling our purpose," said Christopher Boerner, Ph.D., Board Chair & Chief Executive Officer, Bristol Myers Squibb. "We recognize ESG is a journey of continuous improvement, and our entire team is committed to advancing sustainability."

    In 2023, BMS conducted a global ESG materiality assessment to understand evolving stakeholder views and ensure its business priorities reflect the rapidly changing landscape. These insights enabled the company to evolve its ESG strategy, focusing on three key pillars: advancing patient health around the world; expanding the boundaries of science; and fostering a high-performing and inclusive global workforce. At the same time, BMS will continue to amplify its strong performance across material topics such as patient safety and product quality, ethics and conduct, as well as environmental sustainability.

    About Bristol Myers Squibb
    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

    Cautionary Statement Regarding Forward-Looking Statements
    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the Company's goals, strategies, and performance in accordance with its 2023 Environmental, Social, and Governance (ESG) Report. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    MEDIA CONTACT:
    Media@bms.com

    Read More

    View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.

    Contact Info:
    Spokesperson: Bristol Myers Squibb Company
    Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
    Email: info@3blmedia.com

    SOURCE: Bristol Myers Squibb Company



    View the original press release on accesswire.com


    The Bristol-Myers Squibb Stock at the time of publication of the news with a raise of +0,77 % to 47,74EUR on Tradegate stock exchange (08. April 2024, 12:55 Uhr).
    Der Analyst erwartet ein Kursziel von 39,18$, was einem Rückgang von -2,67% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
    Übernehmen
    Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
    Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
    Alternativ können Sie auch unsere Derivate-Suchen verwenden
    Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
    WerbungDisclaimer


    Diskutieren Sie über die enthaltenen Werte


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversityNORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers Squibb Company Bristol Myers Squibb (NYSE: BMY) today published its 2023 …

    Artikel zu den Werten

    Schreibe Deinen Kommentar

    Disclaimer